PRF Technologies (PRFX) Free Cash Flow (2020 - 2024)
PRF Technologies (PRFX) posted quarterly Free Cash Flow of $3.5 million for Q2 2024, up 276.49% year-on-year from $938947.8 in Q3 2023, and up 195.85% on a QoQ basis from -$3.7 million in Q1 2024.
PRF Technologies (PRFX) Free Cash Flow (2020 - 2024) Analysis & Trends
PRF Technologies (PRFX) has reported Free Cash Flow for 5 consecutive years, with $3.5 million the latest figure, recorded in Q2 2024.
- Quarterly Free Cash Flow rose 276.49% year-over-year to $3.5 million in Q2 2024, while the trailing twelve-month figure through Dec 2025 was $3.5 million (up 305.28% YoY) and the FY2025 annual result came in at -$4.0 million, up 68.68% from the prior year.
- Free Cash Flow rose to $3.5 million in Q2 2024 per PRFX's latest filing, from -$3.7 million in the prior quarter.
- Over the last five years, Free Cash Flow for PRFX reached as high as $4.8 billion in Q4 2021 and fell as low as -$4.8 billion in Q3 2021.
- A 5-year average of -$1.2 million and a median of -$1.5 million in 2022 frame the typical range for Free Cash Flow.
- The largest YoY upside for Free Cash Flow was 236154.13% in 2021 against a maximum downside of 2181895.43% in 2021.
- Year by year, Free Cash Flow stood at -$2.0 million in 2020, then jumped by 236154.13% to $4.8 billion in 2021, then slumped by 100.06% to -$2.9 million in 2022, then surged by 45.29% to -$1.6 million in 2023, then jumped by 325.3% to $3.5 million in 2024.
- According to Business Quant data, Free Cash Flow over the past three periods registered $3.5 million, -$3.7 million, and -$1.6 million for Q2 2024, Q1 2024, and Q4 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -208.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 291.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -373.37 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 363.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 348.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 144.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -38.00 Mn |
| 10 | PRF Technologies | 745,168.93 | 451,168.93 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 3.54 Mn |
| Jun 30, 2024 | 3.54 Mn |
| Mar 31, 2024 | -3.69 Mn |
| Mar 31, 2024 | -3.69 Mn |
| Dec 31, 2023 | -1.57 Mn |
| Dec 31, 2023 | -1.57 Mn |
| Sep 30, 2023 | -1.16 Mn |
| Sep 30, 2023 | -1.16 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Jun 30, 2023 | -2.00 Mn |
| Mar 31, 2023 | -1.95 Mn |
| Mar 31, 2023 | -1.95 Mn |
| Dec 31, 2022 | -2.87 Mn |
| Dec 31, 2022 | -2.87 Mn |
| Sep 30, 2022 | -892,000.00 |
| Sep 30, 2022 | -892,000.00 |
| Jun 30, 2022 | -1.35 Mn |
| Jun 30, 2022 | -1.35 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Mar 31, 2022 | -1.35 Mn |